Despite a surge to over 2,500 startups, India's biotech sector needs a shift toward long-term investment and a stronger bridge between academic research and commercial viability to scale globally.

  • India now hosts over 2,500 biotech startups, signaling a shift from manufacturing to innovation.
  • Critical growth areas include AI-enabled drug discovery, genomics, and cell/gene therapy.
  • A four-fold increase in patents over the last decade highlights rising research capacity.

Speaking at the Biotech Conclave 2026 in Chennai, Ajay Mahipal, co-founder and general partner of HealthKois, provided a critical assessment of India's burgeoning biotechnology ecosystem. While acknowledging the impressive growth in the number of startups, Mahipal emphasized that the next phase of evolution requires a fundamental shift in how capital is deployed.

The core issue, according to Mahipal, is the appetite for quick returns. Biotechnology, by its very nature, involves long gestation periods and high risk. He argued that for India to truly transition from a manufacturing hub to an innovation powerhouse, the ecosystem needs "patient capital"—investments that prioritize long-term scientific breakthroughs over immediate quarterly gains.

Read Also:OpenAI Executive Exodus Continues as Brad Lightcap Announces Departure

High-Growth Verticals and Investor Interest

The landscape of biotech investment in India is diversifying. Several cutting-edge fields are currently attracting significant attention from venture capitalists and strategic investors:

  • Cell and Gene Therapy: Moving toward curative treatments for genetic disorders.
  • Precision Medicine: Tailoring healthcare to individual genetic profiles.
  • AI-Enabled Drug Discovery: Using machine learning to slash the time and cost of bringing new drugs to market.
  • Microbiome and Immunology: Exploring the complex relationship between the immune system and microbial flora.

Why This Matters

BozokMedia analysis shows that the gap between laboratory discovery and market adoption remains the "valley of death" for many Indian startups. While the intellectual capacity is present, the lack of an integrated commercialization pipeline prevents India from capturing the high-value end of the global biotech value chain.

"Researchers must adopt an end-to-end mindset, looking beyond the lab to intellectual property, commercialization, adoption, and monetization."

The surge in intellectual property is a positive indicator, with patents increasing four-fold over the last decade. However, Mahipal warned that patents alone are not a business model. He urged young entrepreneurs to focus on solving clearly defined problems and addressing large markets with a viable monetization strategy to attract serious investment.

Furthermore, while collaboration between universities, hospitals, and industry is improving, it remains a work in progress. Mahipal encouraged researchers to maintain a "commercial hat" while pursuing scientific curiosity, ensuring that their innovations have a clear path to the patient.

Did You Know?: Indian biotech patents have grown by 400% in the last ten years, reflecting a massive surge in domestic R&D activity.

Frequently Asked Questions

Q1: Why is long-term capital specifically needed for biotech?
A: Unlike software, biotech involves rigorous clinical trials and regulatory approvals that can take years, making short-term investment cycles incompatible with the science.

Q2: What should young biotech entrepreneurs focus on to get funded?
A: They should focus on solving a specific, large-market problem and have a clear strategy for how the product will be monetized and adopted by the healthcare system.